Crystalline Imidazole Polymorphs for Mitochondria and Cardiovascular Treatment
Summary
USPTO published patent application US20260098015A1 for crystalline polymorphic forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole. The compound is directed to treating mitochondria-related disorders and cardiovascular disorders or conditions. The application was filed May 19, 2025 and names Muralikrishna DUVVURI, Donald Herbert LAMUNYON, and Micah Jeffrey BODNER as inventors.
What changed
USPTO published a patent application for crystalline polymorphic forms of a nitro-imidazole compound (5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole) useful for treating mitochondria-related disorders and cardiovascular conditions. The polymorphic forms provide alternative crystalline structures that may offer improved stability, solubility, or manufacturing properties over amorphous forms.
Pharmaceutical companies and biotech firms developing treatments for mitochondrial dysfunction, cardiovascular diseases, or related therapeutic areas should review this application as potential prior art. Generic drug manufacturers and research institutions may identify opportunities for licensing negotiations or design-around strategies. The publication establishes a priority date of May 19, 2025 for the disclosed crystalline forms and treatment methods.
What to do next
- Monitor for patent issuance and evaluate licensing opportunities
- Review for potential prior art conflicts with existing drug development programs
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CRYSTALLINE FORMS OF 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-1H-IMIDAZOLE
Application US20260098015A1 Kind: A1 Apr 09, 2026
Inventors
Muralikrishna DUVVURI, Donald Herbert LAMUNYON, Micah Jeffrey BODNER
Abstract
The present disclosure relates to polymorphic forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole for treating various disorders or conditions, including mitochondria-related disorders or conditions and cardiovascular disorders or conditions.
CPC Classifications
C07D 233/91 A61K 31/4168
Filing Date
2025-05-19
Application No.
19211720
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.